PulseAugur
EN
LIVE 18:16:48
中文(ZH) 赢官司、融新钱，他想把百万「抗癌针」变平价

Bay Island Cell secures 140M RMB for affordable CAR-T therapy development

By PulseAugur Editorial · [1 sources] ·

Bay Island Cell, a biotech firm founded by Fan Xiaohu, has secured 140 million RMB in Series A funding led by Songhe Capital. The company is developing a non-gene-edited universal CAR-T technology platform, aiming to produce CAR-T therapies that are more affordable and scalable, akin to standard biologics. Fan Xiaohu, formerly of Legend Biotech, aims to overcome the high cost and long production times associated with current CAR-T treatments, presenting early human trial data at the American Society of Clinical Oncology (ASCO) annual meeting. AI

IMPACT This development in cell therapy could lead to more accessible treatments for various diseases, potentially impacting the broader healthcare landscape.

RANK_REASON Significant funding round for a biotech company developing a novel therapeutic approach. [lever_c_demoted from significant: ic=1 ai=0.4]

Read on 36氪 (36Kr) →

AI-generated summary · Google Gemini · from 1 sources. How we write summaries →

Bay Island Cell secures 140M RMB for affordable CAR-T therapy development

How we ranked this

Signal score
0 / 100
Composite score across the factors below. Higher = stronger signal that this story matters right now.
Newsworthiness bucket
Research
Significant funding round for a biotech company developing a novel therapeutic approach. [lever_c_demoted from significant: ic=1 ai=0.4]
Source corroboration
Single-source cluster
Only one publisher covered this so far. Single-source stories can still rank when the publisher is high-authority, but they lack cross-source corroboration.
Topics
funding, product
Editorial topic classification. Feeds into how the story surfaces on /topic/<slug> hub pages and into the per-entity coverage mix.
AI-industry relevance
Standard
On-topic for AI-industry coverage; kept in the public index.
Story freshness
90 days old
Aged out of breaking-news scoring windows; ranking reflects the durable signal from the full source set.

Full methodology in our editorial standards.

COVERAGE [1]

  1. 36氪 (36Kr) TIER_1 中文(ZH) ·

    Winning lawsuits, raising new funds, he wants to make the million-dollar "anti-cancer needle" affordable

    <p>文 | 胡香赟</p> <p>编辑 | 海若镜</p> <p>36氪获悉，前传奇生物创始人/首席科学家范晓虎创办的生物科技公司深圳湾岛细胞，近日完成1.4亿人民币A轮融资，本轮融资由松禾资本领投、东方富海跟投。</p> <p>过去一年，AI像一束强光照亮着资本市场。光芒之外，很多赛道在阴影中被重新定价，创新药板块正是其中之一。潮水褪去，人群对新药好药的需求仍在，创业者们也正在更严苛的估值坐标系里，渡过科学、临床和商业化的一关又一关。</p> <p>在中国细胞与基因治疗（CGT）领域，“范晓虎”这个名字很难被绕开。2022年3月，他主导的传奇生物细胞…

RELATED ENTITIES

RELATED TOPICS